Feifei Nan
Impact in
-
- Lymphoma Diagnosis and Treatment
- Oncology top 5%
- Viral-associated cancers and disorders
- CAR-T cell therapy research
- Cancer Cells and Metastasis
Papers in
-
- Lymphoma Diagnosis and Treatment 21
- Oncology 18
- Viral-associated cancers and disorders 5
- CAR-T cell therapy research 5
- Cancer-related Molecular Pathways 3
- Cancer Cells and Metastasis 2
- Co-authors
- Yu Chang (27 shared papers)Zhaoming Li (27 shared papers)Xiaorui Fu (30 shared papers)Huanle Zhang (2 shared papers)Lei Zhang (21 shared papers)Zhenchang Sun (21 shared papers)Jingjing Wu (20 shared papers)Xinhua Wang (20 shared papers)
- Journals
- Blood (2 papers)Oncotarget (2 papers)Leukemia Research (2 papers)Journal of Clinical Oncology (2 papers)Biochemical and Biophysical Research Communications (2 papers)
- Partner nations
- ChinaUnited States
In The Last Decade
Feifei Nan
38 papers receiving 803 citations
Peers
Comparison fields: 5 of 65
- Pathology and Forensic Medicine 370
- Oncology 388
- Immunology 219
- Cancer Research 121
- Genetics 66
Countries citing papers authored by Feifei Nan
This map shows the geographic impact of Feifei Nan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Feifei Nan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Feifei Nan more than expected).
Fields of papers citing papers by Feifei Nan
This network shows the impact of papers produced by Feifei Nan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Feifei Nan. The network helps show where Feifei Nan may publish in the future.
Co-authors
The 25 scholars most cited alongside Feifei Nan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 39 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2018 | 155 | |
| 2 | 2016 | 103 | |
| 3 | 2010 | 93 | |
| 4 | 2010 | 69 | |
| 5 | 2013 | 31 | |
| 6 | 2018 | 31 | |
| 7 | 2018 | 28 | |
| 8 | 2019 | 25 | |
| 9 | 2017 | 21 | |
| 10 | 2018 | 21 | |
| 11 | Targeting Six1 by lentivirus-mediated RNA interference inhibits colorectal cancer cell growth and invasion. | 2014 | 20 |
| 12 | 2020 | 18 | |
| 13 | 2018 | 18 | |
| 14 | 2015 | 18 | |
| 15 | 2016 | 17 | |
| 16 | 2015 | 15 | |
| 17 | 2020 | 14 | |
| 18 | 2017 | 14 | |
| 19 | 2020 | 12 | |
| 20 | 2020 | 11 |
About Feifei Nan
Feifei Nan is a scholar working on Pathology and Forensic Medicine, Oncology, Immunology, Molecular Biology and Neurology, having authored 39 papers that have together received 810 indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (21 papers), Viral-associated cancers and disorders (5 papers), Immune Cell Function and Interaction (5 papers), CAR-T cell therapy research (5 papers), CNS Lymphoma Diagnosis and Treatment (4 papers), Cancer-related Molecular Pathways (3 papers), T-cell and Retrovirus Studies (2 papers) and Cancer Cells and Metastasis (2 papers). The work is most often cited by research in Pathology and Forensic Medicine (370 citations), Oncology (388 citations), Immunology (219 citations), Cancer Research (121 citations) and Genetics (66 citations). Feifei Nan has collaborated with scholars based in China and United States. Frequent co-authors include Yu Chang, Zhaoming Li, Xiaorui Fu, Huanle Zhang, Lei Zhang, Zhenchang Sun, Jingjing Wu, Xinhua Wang, Jiaqin Yan and Yuqing Li. Their work appears in journals such as Blood, Oncotarget, Leukemia Research, Journal of Clinical Oncology and Biochemical and Biophysical Research Communications.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.